An AI Platform integrating imaging data and models, supporting precision care through prostate cancer’s continuum
Βy Prof. Daniele Regge [Chief of the Radiology Unit, Candiolo Cancer Institute, Torino-Italy] and Simone Mazzetti [Candiolo Cancer Institute, Torino-Italy] The clinical validation study was designed to assess the diagnostic performance of artificial intelligence (AI)...
Βy Paris Ziogkas, the Co-Founder | CEO at Advantis Medical Imaging As the ProCAncer-I project reaches its conclusion, we celebrate a collective achievement that stands as a beacon of what European collaboration can deliver at the forefront of medical AI....
Βy Simone Mazzetti [Candiolo Cancer Institute, Torino-Italy] Acquisition of high-quality magnetic resonance imaging (MRI) examinations is essential for the accurate detection and characterization of prostate cancer, as poor image quality can obscure lesions and...
Βy Nickolas Papanikolaou [Principal Investigator in Oncologic Imaging at the Fundação Champalimaud] Researchers are using artificial intelligence to improve how prostate cancer is detected and diagnosed through MRI scans. In one part of the project, the goal was to...
Newsletter #8 Contents
FUTURE-AI Anniversary Webinar: “The Future of AI and the Radiology Workforce” by Curtis P. Langlotz, MD, PhD. We are pleased to announce that Curtis P. Langlotz, MD, PhD, Professor of Radiology, Medicine and Biomedical Data Science at Stanford University, will deliver...
Great news!Our paper "Data infrastructures for AI in medical imaging: a report on the experiences of five EU projects" published in European Radiology Experimental, has been the Fourth most cited article for the Impact Factor 2024 calculation. A short award ceremony...
An international and multidisciplinary team, led by researchers from the Champalimaud Foundation, in Lisbon, has developed an artificial intelligence algorithm that improves the reliability of prostate cancer detection based solely on magnetic resonance imaging...
Prostate cancer is the second most commonly diagnosed cancer in men. Conventional screening relies on prostate specific antigen (PSA) levels in the blood, which can indicate prostate abnormalities but lacks specificity. Clinical examination and ultrasound also have...